Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients

  title={Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients},
  author={Hideto Kameda and Koichi Amano and Naoya Sekiguchi and Hirofumi Takei and Hiroe Ogawa and Hayato Nagasawa and Tsutomu Takeuchi},
  journal={Modern Rheumatology},
  pages={442 - 446}
Abstract Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) throughout the world. In Japan, MTX is recommended by the Japanese Ministry of Health, Labour, and Welfare to be given as the second or third DMARD and at a dosage of no more than 8 mg/week. We analyzed the efficacy of MTX in Japanese patients with RA in order to determine whether it is comparable to that in Western countries, where 15–20 mg/week of MTX is used, as well as to elucidate the factors… Expand
Risk Factors Associated With the Cumulative Survival of Low-Dose Methotrexate in 273 Japanese Patients With Rheumatoid Arthritis
Cumulative survival of Methotrexate in Japanese RA patients was the same or slightly better than those in reports from Western countries, with less withdrawals reported due to adverse events or inefficacy. Expand
Good response to methotrexate is associated with a decrease in the gene expression of ABCG2, a drug transporter, in patients with rheumatoid arthritis
Good response to MTX is associated with a decrease in the expression of ABCG2 in patients with RA, according to the baseline expression of six genes involved in the intracellular pharmacokinetics of MTX. Expand
Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial
MTX should be continued at the commencement of ETN therapy, even in RA patients who show an inappropriate response to MTX, despite the superiority of the combination therapy of methotrexate and anti-tumor necrosis factor biological agents. Expand
Continuation of Methotrexate Resulted in Better Clinical and Radiographic Outcomes Than Discontinuation upon Starting Etanercept in Patients with Rheumatoid Arthritis: 52-week Results from the JESMR Study
Clinically, the cumulative probability plot of the American College of Rheumatology (ACR)-N values at Week 52 clearly demonstrated a superior response in the E+M group than in theE group, and MTX should be continued when starting ETN in patients with active RA. Expand
The Japanese experience with biologic therapies for rheumatoid arthritis
Post-marketing surveillance data have been collected for all patients with RA who were treated with biologic agents in Japan to monitor drug safety and clearly demonstrated that only ∼5% of these patients experienced adverse drug reactions toBiologic agents, which were well tolerated. Expand
Genetic polymorphisms of enzyme proteins and transporters related to methotrexate response and pharmacokinetics in a Japanese population
The variations in allelic frequencies in different ethnic and/or population groups in healthy adults and RA patients may contribute to individual variations in MTX response and toxicity. Expand
The impacts of gene polymorphisms on methotrexate in Chinese psoriatic patients
The influence of gene polymorphisms has not been reported in the Chinese psoriatic patients and the metabolic processes of MTX include various proteins and genes. Expand
Good response to methotrexate is associated with a decrease in the gene expression of the drug transporter ABCG2 in patients with rheumatoid arthritis
Satoshi Muto Toho University Nana Minamitani Toho University Takehisa Ogura Toho University Arata Nakajima Toho University Koichi Nakagawa Toho University Toru Masaka Toho University Sumiko HiuraExpand
Sex Differences in mRNA Expression of Reduced Folate Carrier‐1, Folypolyformyl Glutamate Synthase, and γ‐Glutamyl Hydrolase in a Healthy Japanese Population
Healthy Japanese adults in this study showed sex‐specific differences in mRNA expression that differed among RFC‐1, FPGS, and GGH, which might contribute to the variation in the efficacy/toxicity of MTX in patients with RA. Expand


Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis
MTX toxicity, final dose, and efficacy are influenced by folate supplementation, and baseline characteristics predicting the outcome of MTX treatment are mainly prior GI events, body mass index, sex, use of NSAIDs, and creatinine clearance. Expand
Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis.
A general trend, although not significant, was found toward a dose toxicity relationship, and a general trend occurred more commonly with MTX. Expand
Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy.
MTX was an effective treatment for RA in this 132 month prospective study and significant improvement was noted in the number of painful joints, swollen joints, and physician and patient global assessments. Expand
Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components
This study suggests that an early initiation therapy of disease modifying drug seems to be of benefit, however, this study was unable to demonstrate a clinically relevant superiority of the combination therapy although several outcomes were in favour of this observation. Expand
Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study
Current dosing strategies should be re-evaluated, and coping strategies for common AEs should be investigated, to achieve better drug retention of LEF. Expand
Efficacy of low-dose methotrexate in rheumatoid arthritis.
It is concluded that this trial provides evidence of the short-term efficacy of methotrexate in rheumatoid arthritis, but the mechanism of action is unknown and longer trials will be required to determine the ultimate safety and effectiveness of this drug. Expand
Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration.
RA patients with longer disease duration do not respond as well to treatment compared with patients with early disease, and female sex, prior DMARD use, disease functional class, and disease activity also have effects on the likelihood of patient response to treatment. Expand
Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.
In patients with active, long-standing RA, blocking TNF-alpha is more effective and better tolerated than MTX monotherapy. Expand
The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases.
  • D. Furst
  • Medicine
  • British journal of rheumatology
  • 1997
Methotrexate is clearly effective in the treatment of rheumatoid arthritis and may be able to decrease the rate of formation of new bony erosions, and is also effective in psoriatic arthritis and is being used in a multiplicity of other rheumatic diseases. Expand
[Clinical relapse of rheumatoid arthritis (escape phenomenon) during low-dose methotrexate therapy].
It is suggested that clinical relapse is not rare in RA patients during low-dose methotrexate therapy, but could be improved by increasing dose. Expand